This CPB is revised to state that imiglucerase, taliglucerase alpha and velaglucerase alpha (VPRIV) are considered medically necessary for persons diagnosed with neuronopathic Type 3 Gaucher disease who meet medical necessity criteria and have neurologic findings consistent with Type 3 Gaucher disease. This CPB is revised to remove reference to alglucerase (Cerezyme) as this product has been withdrawn from the market.